Which Gene is a Dominant Predictor of Response During FOLFOX Chemotherapy for the Treatment of Metastatic Colorectal Cancer, the MTHFR or XRCC1 Gene?

Author： Suh Kwang   Kim Joo   Kim Do   Kim Young   Lee Chulho   Choi Sungho  

Publisher： Springer Publishing Company

ISSN： 1068-9265

Source： Annals of Surgical Oncology, Vol.13, Iss.11, 2006-11, pp. : 1379-1385

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer?

By Lindsay Colin R   Roxburgh Patricia   Graham Janet  

Future Oncology, Vol. 9, Iss. 6, 2013-06 ,pp. : 825-829

Future Medicine

Access to resources Recommend Favorite

Arg399Gln polymorphism of XRCC1 gene and risk of colorectal cancer in Kashmir: A case control study

By                

Oncology Letters, Vol. 5, Iss. 3, 2013-01 ,pp. : 959-963

Spandidos Publications

Access to resources Recommend Favorite

Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer: A prospective study

By Amadori D.  

Breast Cancer Research and Treatment, Vol. 43, Iss. 1, 1997-03 ,pp. : 7-14

Springer Publishing Company

Access to resources Recommend Favorite

Multidrug Resistance Gene-1 Is a Useful Predictor of Paclitaxel-Based Chemotherapy for Patients with Ovarian Cancer

By Kamazawa S.   Kigawa J.   Kanamori Y.   Itamochi H.   Sato S.   Iba T.   Terakawa N.  

Gynecologic Oncology, Vol. 86, Iss. 2, 2002-08 ,pp. : 171-176

Academic Press

Access to resources Recommend Favorite

Two novel variants in the 3′UTR of the BRCA1 gene in familial breast and/or ovarian cancer

By Lheureux Stéphanie  

Breast Cancer Research and Treatment, Vol. 125, Iss. 3, 2011-02 ,pp. : 885-891

Springer Publishing Company

Access to resources Recommend Favorite